<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615845</url>
  </required_header>
  <id_info>
    <org_study_id>PMC-DC-01</org_study_id>
    <nct_id>NCT04615845</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC)</brief_title>
  <official_title>An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Cancer Immunotherapy With Autologous Dendritic Cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmicell Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmicell Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study to evaluate the safety of cancer immunotherapy with autologous dendritic&#xD;
      cells(DC) in patients with metastatic castration resistant prostate cancer (mCRPC)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety of an autologous dendritic cell anticancer immune cell therapy&#xD;
      (Cellgram-DC-PC) for the treatment of prostate cancer in patients with metastatic&#xD;
      castration-resistant prostate cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Measure CTCAE of Safety</measure>
    <time_frame>For 28 weeks</time_frame>
    <description>The level of Adverse Event (AE) is described in accordance with the Common Terminology Criteria for Adverse Event (CTCAE) (Version 5.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response evaluation (INF-r)</measure>
    <time_frame>0, 2, 8, 16 and 28 weeks</time_frame>
    <description>The tumor antigen-specific immune response induced after administration compared to before Investigational Product(IP) administration was confirmed by measuring changes in the secretion of cytokines INF-r in serum (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response evaluation (IL-12)</measure>
    <time_frame>0, 2, 8, 16 and 28 weeks</time_frame>
    <description>The tumor antigen-specific immune response induced after administration compared to before Investigational Product(IP) administration was confirmed by measuring changes in the secretion of cytokines IL-12 in serum (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of changes in tumor marker test results (PSA)</measure>
    <time_frame>0, 2, 4, 8, 16 and 28 weeks</time_frame>
    <description>Changes in tumor marker test results (PSA) are measured at each time point (V4, V5, V6, V7, V8) after administration compared to before (V3) Investigational Product(IP) administration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Castration Resistant Prostate Cancer, CRPC</condition>
  <arm_group>
    <arm_group_label>Cellgram-DC-PC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cellgram-DC-PC is injected subcutaneously near the inguinal lymph nodes</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cellgram-DC-PC</intervention_name>
    <description>Patients will receive 3 times every 2 weeks injection of Cellgram-DC-PC(Autologous dendritic cell) subcutaneously near the inguinal lymph nodes</description>
    <arm_group_label>Cellgram-DC-PC</arm_group_label>
    <other_name>Autologous dendritic cell anti-cancer immune cell therapy for prostate cancer treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 20 and under 81 years&#xD;
&#xD;
          2. Histologically confirmed prostate adenocarcinoma&#xD;
&#xD;
          3. Patients with stage M1a or M1b with extrapelvic lymph nodes and bone metastases&#xD;
&#xD;
          4. Patients diagnosed with castration-resistant prostate cancer after failure of male&#xD;
             hormone deprivation therapy (Castrate levels of testosterone &lt;50 ng/dL)&#xD;
&#xD;
               1. Biochemical progression: Prostate Specific Antigen (PSA) increases three times in&#xD;
                  a row at 1 week intervals, two 50% increases compared to the lowest point, PSA&gt;&#xD;
                  2ng/mL, or&#xD;
&#xD;
               2. Radiological progression: appearance of new lesions; 2 or more new lesions on the&#xD;
                  bone scan&#xD;
&#xD;
          5. Asymptomatic or mild patients after previous treatment&#xD;
&#xD;
               1. Patients who have not used narcotic analgesics within 21 days prior to enrollment&#xD;
&#xD;
               2. Patients with an average weekly pain of less than 4 on the Visual Analogue&#xD;
                  Scale(VAS) (out of 10)&#xD;
&#xD;
          6. Combination of Luteinizing hormone-releasing hormone(LHRH) analogs (leuprolide&#xD;
             (Lupron, Viadur, Eligard) and goserelin (Zoladex, etc.) for the inhibition of&#xD;
             gonadotropin is allowed&#xD;
&#xD;
          7. Whole body performance status: European Cooperative Oncology Group(ECOG) 0~1&#xD;
&#xD;
          8. Patients whose life expectancy is at least 6 months or longer&#xD;
&#xD;
          9. Hb ≥ 8.0g/dL, Absolute Neutrophil Count(ANC) ≥ 1,500/mm3, Platelets ≥ 100,000/mm3&#xD;
&#xD;
         10. Serum Creatinine ≤ 1.5 x Upper Limit of Normal(ULN) or Serum Creatinine&gt; 1.5 x ULN and&#xD;
             Calculated Creatinine Clearance&gt; 30mL/min&#xD;
&#xD;
         11. Total Bilirubin ≤ 1.5 x ULN or Direct bilirubin ≤ ULN, Aminotransferase (AST)/Alanine&#xD;
             aminotransferase(ALT) &lt;2.5 x ULN&#xD;
&#xD;
         12. Patients who did not receive surgery, radiation therapy, or immunotherapy within the&#xD;
             last 6 weeks and recovered from side effects&#xD;
&#xD;
         13. Patients who agreed to use medically recognized contraceptive methods during the&#xD;
             clinical trial participation period&#xD;
&#xD;
         14. Patients who voluntarily participated in clinical trials and signed the Informed&#xD;
             Contents Form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have a local recurrence and are scheduled for local treatment.&#xD;
&#xD;
          2. Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years&#xD;
&#xD;
          3. Patients with visceral metastases (metastases to the lungs, liver, adrenal glands,&#xD;
             peritoneum, brain, etc.)&#xD;
&#xD;
          4. Patients who previously received anti-tumor immunotherapy (anti-PD1, anti-PDL1 or&#xD;
             anti-PDL2, etc.) or participated in immunotherapy-related clinical trials&#xD;
&#xD;
          5. Patients with active autoimmune diseases requiring systemic immunosuppression&#xD;
             treatment (e.g., immunosuppressants such as cyclosporin A or azathioprine or steroids&#xD;
             for disease control)&#xD;
&#xD;
          6. Patients with medical conditions requiring continuous or intermittent administration&#xD;
             of systemic steroids or immunosuppressants&#xD;
&#xD;
          7. Patients who received blood products (limited to whole blood products) within 4 weeks&#xD;
             of screening criteria, or patients who received colony stimulating factors (Colony&#xD;
             Stimulating Factor or recombinant Erythropoietin)&#xD;
&#xD;
          8. Patients with a history of organ or hematopoietic stem cell transplantation&#xD;
&#xD;
          9. Patients with acute or chronic infections requiring systemic treatment&#xD;
&#xD;
         10. Patients known to be infected with human immunodeficiency virus (HIV)/serum positive&#xD;
&#xD;
         11. Patients with active hepatitis A, B or C&#xD;
&#xD;
         12. Patients with untreated syphilis (Fluorescent Treponemal Antibody Absorption Test&#xD;
             (FTA-ABS) Immunoglobulin M positive patients)&#xD;
&#xD;
         13. Patients expected to require therapeutic biotherapy or immunotherapy&#xD;
&#xD;
         14. Patients who received live virus vaccines (e.g. measles, mumps, rubella, chickenpox,&#xD;
             yellow fever, rabies, Bacillus Calmette-Guerin (BCG), oral typhoid vaccine, Flu-Mist,&#xD;
             etc.) within 30 days&#xD;
&#xD;
         15. Patients with a history of anaphylaxis to gentamicin&#xD;
&#xD;
         16. Others, if the person in charge of the study determines that it is not suitable for&#xD;
             the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chungsu Kim, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JIYEOUN JEONG</last_name>
    <phone>82-2-3496-0134</phone>
    <email>jyjeong@pharmicell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalsan You, PhD</last_name>
      <phone>82-2-3010-3979</phone>
      <email>dalsanyou@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Chungsu Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

